compounded glp‑1 weight loss
7 Shocking Truths About Prescription Weight Loss
In 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list, a move that threatens low-cost GLP-1 weight-loss options. Patients who depend on compounded drugs could see their monthly costs triple as insurers shift to brand-name inventory. Medical Disclaimer: This article is for informational purposes